|
|
Biotech
|
|
||
Re: Early snips & notes$SAVA Provides Updates Regarding Phase 2b Study of PTI-125.High Variability in Levels of Biomarkers in Control Arm of Phase 2b Study May Drive Reassessment of Overall Study Results $BMY Bristol Myers' Orencia shows sustained benefit in post-market RA study CITI increasing $DXCM PT to $440 from $361, reiterating our Buy rating; 2) increasing $TNDM PT to $94 from $81 yet maintain our Neutral rating; and 3) there is no change to $PODD PT of $250 and maintain our Buy rating. |
return to message board, top of board |